Fri, Aug 22, 2014, 5:58 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell Oct 18, 2013 4:59 PM Flag

    Cabozantinib data another look

    As Paul mentioned, Exelixis announced Thursday patient enrollment in the COMET-1 study of cabozantinib in advanced, post-chemo, prostate cancer patients has completed. Importantly, Exelixis will have results from an interim analysis of the study this year, and perhaps the final analysis, too, if necessary.
    This means Exelixis CEO Michael Morrissey now gets to stand up in front of investors and tell them the release of pivotal cabozantinib data is a near-term event. He'll find investors receptive to this message this fall and especially in January at the big J.P. Morgan healthcare conference.
    With Exelixis shares stuck in the $5 range, the risk-reward for the COMET-1 study looks favorable.
    This is not to say there is no risk in the COMET-1 study (or the COMET-2) study. I just see the bull-bear battle over whether cabozantinib works or not in prostate cancer being waged in 2014 at a higher Exelixis stock price than where it sits today. Remember, too, the drug is already approved in medullary thyroid cancer and phase II studies in prostate cancer have yielded plenty of positive data.
    If you've forgotten about Exelixis in 2013 -- and who can blame you -- it's time to take another look.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • up !
      Henry

      Sentiment: Strong Buy

    • That was a zSeeking Alpha article.

      • 1 Reply to clemcaldwell
      • $$$$
        Given the dynamics of current investigative work surrounding the clinical relationship between bone scan response and OS -Cabo approval in the prostate space will forever change the science, the treatment paradigm, the understanding of the underlying disease biology, and perhaps even create a new understanding of future targeted approaches and the ways that cell signaling pathways interact.
        Not merely a game-changer, but a thought changer...A policy changer...

        From the standpoint of it's outstanding utility as a remarkably responsive research tool, Cabo plays to a large audience. The researchers that have elected to participate in the Cabo story represent a virtual "Who's Who" of Oncolgy research. Thus, the validatiion of Cabo's unique effect on late-stage cancers has been very expensive... But, look where that money has gone...and look at the $10's of millions of dollars that have come in from IST's, NIH funding, and independent research teams. Cabo has even begun to enjoy celebrity status out of Cedar-Sinai's Ochsner Cancer Center.
        Cabo's goes Hollywood...!!

        Add to this the institutional backing, the roll-call of the BOD, and the scientific & marketing credentials of the management team...and I see but one potential obstacle - the science of the underlying biology itself...the greatest unknown of all.

        The political impact of Cabo approval is largely unknown, but the Big Players have certainly been paying attention - and I harbor the belief that it has been far too early in the science of combo-MET inhibition to fast-track Cabo, given it's toxicity. Instead, we've seen a massive increase in MET/VEGFR combination research. The science is screaming to be understood.

        If you're not into the Cabo story by now..best of good luck to you...
        If you are long, congratulations on a wearisome and enduring holding pattern.
        But, I feel a healin' pay-off a'coming on...
        GLTA

 
EXEL
4.11+0.02(+0.49%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.